Wild-type (senile) amyloidosis laboratory findings

Wild-type (senile) amyloidosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Wild-type (senile) amyloidosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Wild-type (senile) amyloidosis laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Wild-type (senile) amyloidosis laboratory findings
CDC on Wild-type (senile) amyloidosis laboratory findings
Wild-type (senile) amyloidosis laboratory findings in the news
Blogs on Wild-type (senile) amyloidosis laboratory findings
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Wild-type (senile) amyloidosis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Shyam Patel [2]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[3]Shaghayegh Habibi, M.D.[4]

Overview

Wild-type (senile) amyloidosis is a diagnosis of exclusion. Laboratory tests are conducted to evaluate for the presence or absence AL amyloid protein deposition. The absence of AL amyloid provides a strong clue towards the provisional diagnosis of wild-type (senile) amyloidosis. Cardiac biomarkers are the most important predictors of outcome in amyloidosis.

Laboratory Findings

• Wild-type (senile) amyloidosis is a diagnosis of exclusion.
• Laboratory tests are conducted to evaluate for the presence or absence AL amyloid protein deposition.
• The absence of AL amyloid provides a strong clue towards the provisional diagnosis of wild-type (senile) amyloidosis.

Cardiac

• Cardiac biomarkers are the most important predictors of outcome in amyloidosis.
• They provide a quantitative assessment for cardiac damage and wall strain.
• The biomarkers include:

• Troponin I or Troponin T
• BNP and NT-proBNP

Nervous

• In the case of CNS involvement (carpal tunnel syndrome), the following tests should be ordered for confirmation of the presenting symptoms:
  • Electromyography (EMG) and nerve conduction studies (NCS)